CAR T-Cell Therapy for High-Risk Osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have finished all your planned chemotherapy cycles for high-risk osteosarcoma.
- You had surgery to remove lung tumors if needed, and you've healed from that surgery.
- Your cancer hasn't gotten worse since you started treatment.
- You are well enough to be out of bed and do most daily activities (with maybe some help).
- Your heart, kidneys, liver, and lungs are working well enough for this trial.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
This trial tests a new type of immune cell therapy (4th generation CAR T cells) designed to recognize and attack sarcoma cells. It's for people with advanced or recurrent sarcoma whose tumors have a specific marker.
This trial tests a special type of immune cell (called a CAR T-cell) that is trained to attack sarcoma cells. It is for children, teens, and young adults up to age 40 whose sarcoma has not responded to standard therapy. The treatment is given directly into the tumor, and the goal is to see if it is safe and how well it works.
Hear when a new Pediatric Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.